In 1954 Harman proposed the free radical theory of aging, and in 1972 he suggested that mitochondria are both the source and the victim of toxic free radicals. Interestingly, hypertension is an age-associated disease and clinical data show that by age 70, 70% of the population has hypertension and this is accompanied by oxidative stress. Antioxidant therapy, however, is not currently available and common antioxidants such as ascorbate and vitamin E are ineffective in preventing hypertension. The present review focuses on the molecular mechanisms of mitochondrial oxidative stress and the therapeutic potential of targeting mitochondria in hypertension.
INTRODUCTION
Hypertension is a multifactorial disorder involving perturbations of the vasculature, the kidney, and the central nervous system [1] . Despite treatment with multiple drugs, 37% of hypertensive patients remain hypertensive [2] , likely because of the mechanisms contributing to blood pressure elevation that are not affected by current treatments. Human hypertension is associated with reduced activity of antioxidant enzymes and increased production of reactive oxygen species (ROS: O 2 and H 2 O 2 ) leading to oxidative stress, as measured by lipid and DNA oxidation ( Fig. 1) [3, 4] . Indeed, in almost all experimental models of hypertension ROS are increased in multiple organs, including critical centers of the brain, the vasculature, and the kidney. In the brain, ROS promote neuronal firing, ultimately increasing sympathetic outflow [5, 6] . In the kidney, ROS act in multiple sites to promote sodium resorption and volume retention [7] . In the vasculature ROS promote vasoconstriction and remodeling, increasing systemic vascular resistance [8] . Our group has revealed several sources of ROS contributing to hypertension, including the NADPH oxidase, uncoupled nitric oxide synthase, and the
REGULATION OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES
The major biological function of mitochondria is adenosine triphosphate (ATP) synthesis [13] . This process is based on the transfer of electrons through the mitochondrial respiratory chain coupled with transporting protons (H þ ) from the matrix to the intermembrane space to generate the proton motive force, which is used for conversion of ADP to ATP. Several sites of the electron transport chain 'leak' electrons to O 2 creating O 2 - [14, 15] . This is not a 'spontaneous' process, and the production of mitochondrial ROS is highly regulated [9 && ,10] . It strongly depends on the pH gradient across the inner membrane [16] , activation of mitochondrial ATP-sensitive potassium channels (mitoK þ ATP ) [17, 18] , and the opening of mitochondrial permeability transition pore [19, 20] . Mitochondrial O 2 is rapidly converted to H 2 O 2 by mitochondrial superoxide dismutase (SOD2) [21, 22] , and H 2 O 2 is a neutral molecule which easily leaves mitochondria. We have previously shown that activation of NADPH oxidases increases the production of mitochondrial ROS and vice versa: increase in mitochondrial ROS activates NADPH oxidases [19, 23] . Production of mitochondrial ROS, therefore, is redox-dependent and represents an ongoing feedforward cycle [10] . It is recognized that mitochondrial ROS play an important physiological function [24] ; however, excessive stimulation of mitochondria leads to ROS overproduction and depletion of antioxidants, resulting in imbalance between oxidant production and antioxidant defense system which constitutes an oxidative stress ( Fig. 2 ).
SIRTUIN 3 AND MITOCHONDRIAL SUPEROXIDE DISMUTASE
Mitochondrial SOD2 is a key antioxidant enzyme, and acetylation represents a major posttranslational regulation of SOD2 activity. SOD2 in vivo is activated
KEY POINTS
Hypertension is associated with increased production of mitochondrial superoxide and reduced activity of antioxidant defense system, which contributes to the pathogenesis of hypertension and endorgan dysfunction.
Several risk factors for hypertension, such as aging, smoking, and metabolic conditions, increase mitochondrial oxidative stress, and lifestyle modification reduces mitochondrial dysfunction and attenuate hypertension.
Future studies must be directed to determine the precise molecular mechanisms of mitochondrial oxidative stress in hypertension and validate the therapeutic potential of different mitochondria-targeted strategies.
Oxidants: Oxidative stress is an imbalance between oxidant production and activity of the antioxidant system leading to oxidation of multiple biological targets, such as DNA, proteins, lipids, and nitric oxide, which can be followed by the accumulation of markers of oxidative stress. RNS, reactive nitrogen species; ROS, reactive oxygen species; SOD, superoxide dismutase. by Sirtuin 3 (Sirt3) mediated deacetylation of specific lysine residues [25] . Nicotinamide adenine dinucleotide (NAD þ )-dependent mitochondrial Sirtuin 3 acts as a metabolic sensor, using intracellular metabolites such as NAD þ and acetyl-coenzyme A (CoA) to modulate mitochondrial function to match nutrient supply ( Fig. 3 ) [26] . Access of acetyl-CoA leads to SOD2 hyperacetylation resulting in SOD2 inactivation, and deacetylation by Sirt3 restores SOD2 activity [27] . The profound increase of hypertension with age is associated with the decline of both mitochondrial energy metabolism [28] and the NAD þ -dependent deacetylase activity [29] . Sirt3 is a nuclear-encoded protein, however, the majority of Sirt3 translocates to mitochondria [29] . Clinical studies have shown that Sirt3 expression declines by 40% by age 65, paralleling the increased incidence of hypertension [28, 30] . Angiotensin II and inflammation also mediate the decline in Sirt3 activity [31] . Interestingly, SOD2 expression is not changed with age but the activity of Sirt3 and SOD2 are diminished [32] , suggesting that SOD2 acetylation contributes to hypertension. Indeed, we have shown that SOD2 overexpression attenuates hypertension [23] , whereas SOD2 depletion enhances oxidative stress and hypertension.
There are several genetic and metabolic factors which affect Sirt3 expression and activity. Bellinzi et al. [33] have discovered a variable number tandem repeat polymorphism which has an allele-specific enhancer activity and this activity is virtually absent in men older than 90 years. Authors suggested that Sirt3 underexpression can be detrimental for longevity as it occurs in animal models [34] . Dransfeld et al. [35] have recently identified two nonsynonymous human SIRT3 single-nucleotide polymorphisms (SNPs) and evaluated their impact on SIRT3 activity and stability. It is interesting that multiple risk factors for hypertension are associated with reduced Sirt3 expression and activity. For example, Sirt3 activity is metabolically downregulated by increased Acetyl-CoA and reduced NAD þ in the metabolic syndrome, hyperlipidemia, diabetes, and a sedentary lifestyle, whereas aging and smoking reduces Sirt3 expression ( Fig. 3 ) [30,36 & ]. It has been suggested that dietary supplementation of Sirt3 activating compounds such as resveratrol can be beneficial [37, 38] . Resveratrol supplementation reduced renal inflammation and attenuated hypertension in the animal models [39 & ]; however, recent clinical studies showed mixed results of resveratrol supplementation in cardiovascular disease and human hypertension [40, 41] .
AGING AND MITOCHONDRIAL IMPAIRMENT
Silencing information regulator 2 extends lifespan in yeast, worms, and flies [42] , and sirtuins are silencing information regulator 2 homologs in mammals [43] . SIRT3 is suppressed with aging and SIRT3 upregulation in aged hematopoietic stem cells improves their regenerative capacity [32] . Therefore, Sirt3 is one of the potential candidates for the age-associated development of cardiovascular diseases. Indeed, Sirt3 expression declines by 40% by age 65, paralleling the increased incidence of hypertension [30] . Sirt3 activation of mitochondrial metabolism by deacetylation of key Krebs cycle enzymes, promotes fatty acid b-oxidation, activates complex I, improves antioxidant defense by activation of NADPH producing isocitrate dehydrogenase and increasing SOD2 activity [27, 44] . There is compelling evidence for the accumulation of oxidative damage to specific mitochondrial proteins, which leads to the progressive mitochondrial dysfunction with aging [45] . The role age-associated mitochondrial oxidative stress in hypertension was highlighted in the studies of mice deficient in mitochondrial superoxide dismutase (SOD2 -/þ ), which have age-associated hypertension and increased sensitivity to salt [46] . Recent studies further support the role of mitochondrial oxidative stress in aging, which depresses respiratory function and contribute to muscle atrophy [47] .
The early dysfunction appears to be reversible based on improved mitochondrial function and elevated mitochondrial gene expression after exercise training [48] .
ANGIOTENSIN II AND MITOCHONDRIAL DYSFUNCTION
Interestingly, angiotensin-converting enzyme inhibitor enalapril and angiotensin II type I receptor (AT1R) blocker losartan attenuate age-associated mitochondrial dysfunction [49] . Angiotensin II stimulates ROS production by nonphagocytic NADPH oxidases such as Nox1 and Nox2. We have investigated the potential cross-talk between mitochondria and NADPH oxidases [10] . It was found that depletion of p22phox and Nox1 subunits of NADPH oxidases in endothelial cells completely prevented angiotensin II induced mitochondrial oxidative stress [9
&&
,19]. Furthermore, scavenging of mitochondrial ROS by acute treatments with mitochondria-targeted antioxidants [2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl) triphenylphosphonium (mitoTEMPO)] and mitoEbselen attenuated NADPH oxidase activity and reduced O 2 production in the cytoplasm [9 && ,50]. These data demonstrate redox-dependent cross-talk between cytoplasmic Nox2 and mitochondrial ROS in endothelial cells. Other cell types, however, have different Nox isoforms. Vascular smooth muscle cells, for example, express Nox1 which is upregulated by angiotensin II [51, 52] and, therefore, Nox1 can play an important role in cross-talk between mitochondrial ROS and NADPH oxidase in vascular smooth muscle cells. Indeed, both angiotensin II and mitoK RR ATP activator diazoxide stimulated mitochondrial ROS and NADPH oxidase in rat vascular smooth muscle cells in vitro and in rat aorta [53] . The cross-talk between NADPH oxidases and mitochondrial ROS is bi-directional. Angiotensin II activates NADPH oxidases via the AT1R receptor, whereas expression of AT1R is redox dependent and thereby overproduction of mitochondrial ROS may enhance stimulation of AT1R mediated pathways [11] . NADPH oxidases produce O 2 and H 2 O 2 which increase intracellular Ca 2þ and stimulate redox dependent mitoK þ ATP and PKCe (Fig. 4 ) which triggers Ca 2þ and redox induced production of mitochondrial ROS [18, 50, 54] . Activation of c-Src is redox sensitive and is stimulated by H 2 O 2 [55] , which appears to represent a feed-forward mechanism, whereby mitochondrial H 2 O 2 amplifies NADPH oxidase activity [9 && ]. Mitochondria apparently regulate both expression [56] and the activity of NADPH oxidases [57] . Partial depolarization of mitochondrial membrane potential reduces Ca 2þ uptake by mitochondrial uniporter and increases Ca 2þ -dependent activation of NADPH oxidases [57] , whereas depletion of SOD2 results in an increase of basal and stimulated vascular NADPH oxidase activity [23] . Therefore, overproduction of mitochondrial ROS may result in overstimulation of cytoplasmic NADPH oxidases and dysregulation of cellular signaling, leading to the development of a vicious cycle of oxidative stress [23] . FIGURE 4 . Angiotensin II and inflammation increases reactive oxygen species (ROS) production by NADPH oxidases, which leads to the opening of mitochondrial redox sensitive mitochondrial channels (mPTP and mitoK þ ATP ) and increased acetylation of mitochondrial enzymes. In endothelial cells this stimulates superoxide production by complex I and reduces mitochondrial superoxide dismutase (SOD2) activity, leading to endothelial oxidative stress, impaired vasodilatation, and increased hypertension.
CALORIE RESTRICTION AND MITOCHONDRIAL ANTIOXIDANTS
It has been previously shown that calorie restriction attenuates hypertension in rat models [58] ; however, the exact mechanisms and therapeutic potential of this intervention is not clear. It has been suggested that calorie restriction activates the adenosine monophosphate-activated protein kinase pathway which improves nitric oxide (NO) synthase phosphorylation and endothelial function [58] . Calorie restriction increases the expression of endothelial and neuronal nitric oxide (NO) synthase and enhances NO-mediated mitochondrial biogenesis [59, 60] . Other groups have shown that calorie restriction [25] increases Sirt3 expression and activity, which may suggest that increased Sirt3 activity may reduce hypertension. Recent clinical studies showed a substantial decrease in SBP by 20 mmHg in patients following 1 year of calorie restriction [61] , which can be mediated by a number of pathways. One potential mechanism may include the upregulation of Sirt3 by calorie restriction and Sirt3 stimulated mitochondrial antioxidant defense system (Fig. 5) [62] . The mitochondrial NAD þdependent Sirt3 is upregulated in response to fasting and calorie restriction whereas high-fat diet downregulates Sirt3, leading to mitochondrial protein hyperacetylation and oxidative stress [63] .
Calorie restriction activates Sirt1 and Sirt3, therefore, new sirtuin activators have been developed as calorie restriction mimetics which can be beneficial in age-related disorders [64] . Indeed, preclinical and clinical studies support the role of the sirtuin activator resveratrol in the treatment of cardiovascular diseases [65 && ]. Furthermore, the enzymatic activities of isocitrate dehydrogenase 2, glutathione peroxidase, and SOD2, as well as deacetylation of SOD2, were increased by resveratrol treatment in endothelial cells, supporting the effect of resveratrol through Sirt3 signaling pathway [66] .
PHYSICAL ACTIVITY AND MITOCHONDRIA
Physical activity affects mitochondrial function through multiple pathways, which include shear stress stimulation of NO-mediated mitochondrial biogenesis [60, 67] , metabolic regulations [68 && ], increased antioxidant expression [69] , and NAD þ dependent Sirt3 activation [70] . Endurance exercise attenuates age-associated reduction in Sirt3 expression and improved mitochondrial function (Fig. 5 ) [28] . It is important to note that excessive exercise can induce mitochondrial damage followed by excessive ROS production, NFkB activation, and proinflammatory cytokines formation [71] . Moreover, high-intensity exercise in elderly patients does not reverse age-related mitochondrial damage and dysfunction but can contribute to further alteration of mitochondrial morphology [71] . It is clear that regular exercise reduces mitochondrial oxidative stress and improves mitochondrial function; however, high-intensity exercise should be avoided, particularly in elderly patients.
SMOKING AND MITOCHONDRIAL OXIDATIVE STRESS
Smoking is one of the major risk factors for the development of hypertension [72] . Smoking increases blood pressure both in normotensive and hypertensive patients [73, 74] ; however, smoking cessation success is very limited (7%) [75, 76] , and the risk for cardiovascular diseases remains elevated long after quitting smoking [77, 78] . Smoking increases oxidative stress [79] and causes mitochondrial dysfunction [80, 81] . Cigarette smoke increases O 2 production [82] and reduces Sirt3 levels [36 & ], which can further exacerbate mitochondrial oxidative stress. The precise mechanisms of smoking induced mitochondrial oxidative stress remain elusive.
Clinical studies showed that the accumulation of the lipid oxidation product malondialdehyde in the blood plasma of smokers was increased by 2.5-fold, whereas the activity of major antioxidant enzymes catalase, superoxide dismutase, and glutathione peroxidase were significantly reduced [83] . This leads to oxidation of cysteine and glutathione, and the level of reduced glutathione is diminished in the kidney by 2-fold in mice exposed to cigarette smoke for 4 days [84] . The resultant alteration in the thiol redox status impairs cellular redox signaling and can contribute to cellular and mitochondrial dysfunction. Indeed, smoking a single cigarette rapidly reduces endothelial nitric oxide production and significantly diminishes blood plasma antioxidants [85] . It has been proposed that cigarette smoke induces O 2 production in endothelial cells leading to NO inactivation and NO synthase uncoupling [86] . Finally, cigarette smoke induces metabolic reprograming in mitochondria which contributes to cancer development [81, 87] . These metabolic alterations are associated with NADH accumulation [81] resulting in increased mitochondrial O 2 and reduced SOD2 activity [88] . Interestingly, hypertensive patients with smoking have significantly reduced responses to common classes of antihypertensive drugs, potentially because of metabolic interference between cigarette smoking and drugs [72] , therefore new classes of antihypertensive agents could add to the currently available therapeutic armamentarium to improve the treatment of hypertension. It is possible that new mitochondria-targeted therapeutic approaches can be useful in the treatment of patients with history of smoking.
TARGETING MITOCHONDRIAL OXIDATIVE STRESS IN HYPERTENSION
We have developed a mitochondria-targeted SOD2 mimetic, mitoTEMPO, by conjugating the lipophilic triphenylphosphonium cation to an antioxidant moiety SOD mimetic TEMPO [23] . Our data indicate that mitoTEMPO accumulates several hundredfold within mitochondria, likely because of its positive charge and driven by the mitochondrial membrane potential. This markedly enhances scavenging of mitochondrial O 2 and provides the protection of mitochondrial and cellular function from O 2 overproduction ( Fig. 5 ). Inhibition of mitochondrial oxidative stress with mitoTEMPO supplementation attenuates endothelial oxidative stress, restores NO production, improves endothelium-dependent vasodilatation, and reduces blood pressure in angiotensin II and deoxycorticosterone acetate-salt models of hypertension [23] . have shown significant antihypertensive activity, additional translational studies are required to move mitochondria-targeted antioxidants from bench to the bedside.
There are two currently available mitochondria directed strategies: supplementation with mitochondrial cofactor ubiquinone (CoQ 10 ) and treatment with cardiolipin-protective compound bendavia. Ubiquinone is reduced in hypertension, and CoQ 10 supplementation has an antihypertensive effect (Fig. 5) [89] . It has been suggested that ubiquinone acts as mitochondrial antioxidant. Our studies, however, do not support significant free radical scavenging by Ubiquinone [90] . Ubiquinone primarily functions as electron carrier and it is a critical cofactor in the enzymatic electron transfer in mitochondrial electron transfer chain. Therefore, Ubiquinone can potentially improve oxidative phosphorylation and reduce 'electron leakage' in mitochondria. Bendavia (Stealth BioTherapeutics) is a candidate drug that inhibits cytochrome c/cardiolipin peroxidase activity [91] . As a result, Bendavia protects the structure of mitochondrial cristae and promotes oxidative phosphorylation [92] . In preclinical studies, Bendavia reduced renal and cardiac ischemic injury, mitigated microvascular rarefaction and fibrosis, prevented acute kidney injury, and improved postinfarction cardiac function [93 && ,94,95]. Multiple phase 1 and phase 2 trials studying Bendavia in mitochondrial conditions have found that the drug is well tolerated.
CONCLUSION
In the past decade it has become clear that mitochondrial oxidative stress contributes to hypertension. Several mitochondria-targeted strategies have been developed. However, there are still many questions left unanswered: the precise molecular mechanisms leading to mitochondrial oxidative stress in hypertension and end-organ dysfunction remain unclear; the response of specific cells and tissue to mitochondria-targeted treatments is not known; and the therapeutic potential of targeting mitochondrial regulators of ROS production and antioxidant activity has not been validated. Additional studies are required to address these questions. In the interim, careful attention to preventive strategies and lifestyle modification must be used. The strengths and weaknesses of each approach will help clinicians and researchers to determine which measures are best for each particular situation.
